Press
Biopharmaceutical Research Company Announces First Dose of BRC-002, a First-in-Class Cannabinoid Therapeutic for Complex Regional Pain Syndrome (CRPS), in Investigator-Initiated Study
Biopharmaceutical Research Company Announces First Dose of BRC-002, a First-in-Class Cannabinoid Therapeutic for Complex Regional Pain Syndrome (CRPS), in Investigator-Initiated Study Read more →
First patient received BRC-001, a cannabinoid therapeutic, in a clinical trial investigating supportive care in breast cancer at City of Hope.
City of Hope and Biopharmaceutical Research Company announce first patient has received BRC-001 first-in-class cannabinoid therapeutic, in a clinical trial investigating supportive care in breast cancer Read more →